HomeGeneticsConditionOsteoglophonic dysplasia
Back to Condition
Osteoglophonic dysplasia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Osteoglophonic dysplasia

Osteoglophonic dysplasia is a rare genetic condition characterized by abnormal bone growth, severe craniofacial abnormalities, and short stature.

Overview

The term osteoglophonic refers to bones having distinctive hollowed-out areas that appear as lesions or holes on x-ray images. These lesions typically affect the long bones of the arms and legs. In people with this condition, bones in the skull often fuse together too early, a process known as craniosynostosis, which can result in a flat head appearance.

Symptoms

Characteristic features of osteoglophonic dysplasia include:

  • Craniofacial abnormalities: Prominent forehead, widely spaced and prominent eyes, low-set ears, flattened nasal bridge and mid-face, protruding jaw, and a high arch in the roof of the mouth.
  • Dental issues: Clinical anodontia (teeth never emerge from the jaw) and hypertrophic gingiva (overgrown gums).
  • Skeletal features: Hollowed lesions in long bones (often non-ossifying fibromas), short and bowed legs and arms, overlapping toes, and short, broad hands and fingers.
  • Systemic issues: Failure to thrive in infants, episodes of increased body temperature and excessive sweating, pyloric stenosis, and inguinal hernia.

While intelligence is generally not affected, individuals may experience speech delays. Respiratory problems and difficulty eating or drinking may occur due to the extent of craniofacial abnormalities.

Causes

Osteoglophonic dysplasia is caused by "gain-of-function" variants in the FGFR1 gene. This gene provides instructions for making the fibroblast growth factor receptor 1 protein, which plays a major role in skeletal development, nervous system development, and the regulation of bone growth. The altered protein promotes premature skull fusion and disrupts bone growth in the limbs. It also increases the secretion of the hormone FGF23, leading to abnormal phosphate levels that further impair bone health.

Inheritance

This condition is inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the disorder. Most cases result from new mutations in the gene occurring during the formation of reproductive cells or in early embryonic development, though some individuals inherit the variant from an affected parent.

Frequently Asked Questions

Early cranial vault remodeling is usually performed between 6 and 12 months of age to relieve intracranial pressure and improve head shape; recovery is often 4–6 weeks with gradual return to normal activities. Limb deformities such as bowed legs or overlapping toes may be addressed with osteotomies or guided growth procedures in early childhood; recovery can range from a few weeks to several months depending on the complexity of the surgery.
Feeding difficulties often arise from jaw and airway anomalies; specialized feeding techniques (e.g., high‑calorie, thickened liquids) and, if needed, gastrostomy tubes can ensure adequate nutrition. Respiratory support may involve monitoring for obstructive sleep apnea with overnight pulse oximetry or polysomnography, and in severe cases, temporary tracheostomy or continuous positive airway pressure (CPAP) may be required.
Diagnosis typically begins with a detailed physical exam noting craniofacial features such as a prominent forehead, widely spaced eyes, and a flattened nasal bridge. Imaging studies—especially skull X‑rays and CT scans—reveal premature cranial suture fusion (craniosynostosis) and characteristic hollowed lesions in long bones. Genetic testing for FGFR1 mutations confirms the diagnosis and helps rule out other skeletal dysplasias.
Gain‑of‑function FGFR1 mutations increase secretion of FGF23, leading to hypophosphatemia and impaired bone mineralization. Regular monitoring of serum phosphate, calcium, and alkaline phosphatase levels is recommended, typically every 3–6 months. Treatment may include oral phosphate supplements and active vitamin D analogs to support bone growth and reduce fracture risk.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA